Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

22.16 +0.13 (+0.59%)
Streaming Delayed Price Updated: 1:52 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
From Innoviva, Inc.
Via Business Wire
News headline image
US Stock: Innoviva ↗
Innoviva Incorporated is a healthcare focused asset management company. The Company intends to participate in the development, commercialization, and financial management of bio-pharmaceuticals. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the UBS Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
News headline image
INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024 ↗
INVA stock results show that Innoviva missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 ↗
A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher. 
Via InvestorPlace
News headline image
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge ↗
Discover three high-growth stock picks set for unprecedented surges in the metals, marine transportation, and pharmaceutical industries. 
Via InvestorPlace
News headline image
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs ↗
Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. 
Via Benzinga
News headline image
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
3 Under-$20 Stocks That Could Make You a Fortune ↗
Discover three under-$20 stocks that could make a fortune in the pharmaceuticals, entertainment, and application software industries. 
Via InvestorPlace
News headline image
INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 ↗
INVA stock results show that Innoviva beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the BofA Securities Health Care Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names ↗
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month. 
Via InvestorPlace
News headline image
Chart Of The Day: Innoviva - Individual Investor Favorite ↗
100% technical buy signals 14 new highs and up 12.87% in the last month 36.40+ Weighted Alpha 
Via Talk Markets
News headline image
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
Innoviva to Participate in the Cantor Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
From Innoviva, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.